Participating Institutions
Hugh Sampson, M.D., dean for Translational Biomedical Sciences and the Kurt Hirschhorn Professor of Pediatrics at Mount Sinai School of Medicine, discusses the results of an experiment investigating the cellular mechanisms of peanut allergy. Joining him are student Steven Woo (center) and Wayne Shreffler, M.D., Ph.D. (right), assistant professor of pediatrics at Mount Sinai School of Medicine. (Photo by Matthew Septimus)
Mount Sinai Institutes for Clinical and Translational Sciences
New York, NY
Principal Investigator: Hugh A. Sampson, M.D.
Participating Institutions and Community Partners:
- Lehman College
- Pace University, Lienhard School of Nursing
- Hunter College
- Baruch College
- James J. Peters VA Medical Center
Highlights:
The goal of the Mount Sinai Institutes for Clinical and Translational Sciences (MSICTS) is to establish a research paradigm that will: 1) facilitate bench-to-bedside translation of cutting-edge research; 2) create an academic home for clinical and translational investigators; and 3) supply the governance and resources needed to allow clinical investigators to benefit from Mount Sinai's Translational Research Institutes and potential collaborators.
To accomplish this, MSICTS will redesign its research infrastructure to integrate research functions across departments, enhance and promote interactions between basic scientists and clinical investigators, and streamline administrative procedures for new clinical trials and dissemination of results. It will establish a Translational Discoveries Program to provide consultation, oversight and facilities for clinical and translational research. MSICTS also will engage the community and its affiliates to translate health benefits to the public. And it will develop methodologies to improve trial design and reduce participant burden.
To recruit and retain clinical and translational researchers, MSICTS will train and support new investigators in a multidisciplinary, doctoral degree-granting program in clinical and translational research. It also will develop a recruitment program and enhance career development. An innovative Experimental Therapeutics & Technologies Program will identify and develop novel clinical and translational research projects and connect basic and clinical researchers, caregivers and laboratories through an integrated network of information.
MSICTS will create an effective, efficient and centralized research administrative structure. It will foster and reward interdisciplinary collaborations, educate and retain new clinical and translational investigators and enable translation of basic scientific discoveries into clinical practice. MSICTS also will deliver to its diverse community new therapies and an improved standard of care.